If the chance of having a healthy child consider to be 25 percent and the chance of having a sibling showing HLA compatibility is 20 percent, the IVF-supported PGT should recommend for couples who have a genetic disease or sick child.
Today, transplantation of allogeneic bone marrow has applied the treatment of some hematopoietic diseases: including beta thalassemia and leukemia. Transplantation processes made from HLA-compatible donors produce has successful results in the treatment of these kinds of diseases.
How is HLA-compatible PGT made?
Fragment analysis and genotyping of the gene areas where the mutation is observed in the evaluation of blastomere/trophectoderm, which is taken following the biopsy, and A, B, C and DRB areas of HLA gene are made. It is possible to increase the accuracy of the test by precluding the mistakes that will result from the analysis at least 8 polymorphic STR markers, which located in the HLA area, and also from the possibility of contamination and crossing-over between the HLA genes.
Since the existence rate of a healthy embryo in terms of HLA compatibility and screened mutation is generally 3/16, it is important to obtain as many as an embryo in the IVF treatment.